SCHEMBL1721132

SCHEMBL1721132

O=C1c2ccccc2C(=O)N1[C@H]1CC[C@@H](c2ccccn2)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.46
OPRD1 P41143 1/20 0.46
OPRK1 P41145 1/20 0.46
OPRL1 P41146 1/20 0.46
ALDH1A1 P00352 7/20 0.46
KMT2A Q03164 3/20 0.44
RAB9A P51151 2/20 0.44
MAPT P10636 2/20 0.44
NPC1 O15118 1/20 0.44
KDM4E B2RXH2 3/20 0.42
HPGD P15428 2/20 0.42
TSHR P16473 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GAA P10253 1/20 0.42
CASP1 P29466 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CYP1A2 P05177 1/20 0.41
GRM5 P41594 1/20 0.41
GFER P55789 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1721397 1.00 OPRM1 (0.46) OPRM1OPRD1OPRK1OPRL1ALDH1A1
SCHEMBL1721127 1.00 OPRM1 (0.46) OPRM1OPRD1OPRK1OPRL1ALDH1A1
SCHEMBL1721130 1.00 OPRM1 (0.46) OPRM1OPRD1OPRK1OPRL1ALDH1A1
SCHEMBL1721395 1.00 OPRM1 (0.46) OPRM1OPRD1OPRK1OPRL1ALDH1A1
SCHEMBL13187691 0.80 OPRM1 (0.43) OPRM1OPRD1OPRK1OPRL1ALDH1A1
SCHEMBL3091992 0.75 OPRM1 (0.48) OPRM1OPRL1ALDH1A1KMT2AKDM4E
SCHEMBL3091989 0.75 OPRM1 (0.48) OPRM1OPRL1ALDH1A1KMT2AKDM4E
SCHEMBL26964669 0.74 CYP3A4 (0.39) ALDH1A1KMT2ATSHRGAACYP1A2
SCHEMBL27123247 0.74 CYP3A4 (0.39) ALDH1A1KMT2ATSHRGAACYP1A2
SCHEMBL2665681 0.74 L3MBTL1 (0.54) OPRM1ALDH1A1KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406266-B1 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS KYORIN SEIYAKU KK (JP) 2013-12-25 EP disclosed
EP-2406266-A1 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS Kyorin Pharmaceutical Co., Ltd. (JP) 2012-01-18 EP disclosed
US-8071591-B2 7-cycloalkylaminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-12-06 US disclosed
US-20100234367-A1 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS Kyorin Pharmaceuticals Co. Ltd 2010-09-16 US disclosed
WO-2010104205-A1 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS KYORIN PHARMACEUTICAL CO., LTD. (JP) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234367-A1 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS GSK3B, GSK3A, GSKIP OPRM1 4336/4885OPRD1 3543/4885OPRK1 2782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.